It was announced through his official Twitter account that the Sputnik V vaccine will be cheaper than the American one.
3 min read
As the race for the first viable vaccine against COVID-19 rages on, there’s another problem: price. This Sunday, the official Twitter account of the Russian vaccine Sputnik V announced that it would have a “much lower” price than the one developed in the US by pharmaceutical companies Pfizer / BioNTech and Moderna.
The tweet posted on @sputnikvaccine aims to translate “pharmaceutical terminology” to reveal the real price of American vaccines. Therefore, he states that the Pfizer / BioNTech coronavirus vaccine will cost $ 19.50 per dose, while Modernas is estimated at $ 25 to $ 37 per dose.
“Indeed, This means that its price is $ 39 and $ 50-74 per person. The Pfizer, Sputnik V and Moderna vaccines require two doses per person, ”the publication clarifies.
“”Sputnik V price will be much lower“Is stated in the tweet.
Translation of Pharma Jargon: The advertised price for Pfizer of $ 19.50 and Moderna of $ 25-37 per dose actually means a price of $ 39 and $ 50-74 per person, respectively. The Pfizer, Sputnik V and Moderna vaccines require two doses per person. The price of Sputnik V will be much lower. https://t.co/nr1C7RBdZB
– Sputnik V (@sputnikvaccine) 22nd November 2020
How much does the Russian vaccine against COVID-19 cost?
The exact price of the long-awaited Russian coronavirus vaccine will be announced in the next week, according to a spokesman for the Russian Direct Investment Fund (RDIF).
So far, the vaccine developed by the pharmaceutical company Janssen, part of the Johnson Johnson conglomerate, promises the lowest price. Joaquín Duato, vice president of the executive committee of the American multinational, has put forward costs of less than $ 10 a dose.
See also: Pfizer and BioNTech will apply for an emergency approval for the coronavirus vaccine today
Which vaccine is the most effective so far?
The Sputnik V vaccine was the world’s first registered COVID-19 drug. It was 92% effective based on the first interim phase 3 analysis of clinical trials.
In contrast, the vaccines developed by Pfizer / BioNTech and Moderna were about 95% effective.
Around 40,000 volunteers take part in studies after the drug is registered. More than 20,000 of them have already received the first dose of the drug, while more than 16,000 have already received both doses.